Scholarships break down financial barriers to education

    UCB Pharma Canada Inc. offers 16 one-time scholarships for up to
    $5,000.00 - apply now - deadline for applications is June 30, 2009

    Application packs can be obtained from your physician or by visiting, or for a downloadable
    application form

    BURLINGTON, ON, June 10 /CNW/ - UCB Pharma Canada Inc. is helping to
reduce the financial burden faced by students living with rheumatoid
arthritis, Crohn's disease and ulcerative colitis, through a UCBeyond
scholarship program. This year, the UCBeyond scholarship program will award
eight (8) one-time scholarships of up to $5,000.00 CDN each to people
diagnosed with rheumatoid arthritis and eight (8) one-time scholarships of up
to $5,000.00 CDN each to people diagnosed with Crohn's disease or ulcerative
colitis. The winners must demonstrate academic ambition and use their
scholarship toward post-secondary education (i.e. university, college, trade
school, etc.) for the 2009/10 school year. UCB has, to date, earmarked more
than $245,000 CDN for the allocation of close to 50 scholarships.
    "Receiving the UCBeyond Rheumatoid Arthritis Scholarship has allowed me
to focus on my education without thinking about the cost," says Jessica Leyte,
recipient of a 2008 UCBeyond Rheumatoid Arthritis Scholarship. "This is a
valuable program for students like me who are faced with a chronic illness and
the physical, academic and financial challenges that come with it."
    "UCB is dedicated to maintaining initiatives like the UCBeyond
scholarship program to create access to education for students dedicated to
reaching beyond the boundaries of chronic illness," says Anne de Cassini,
General Manager of UCB Pharma Canada Inc. "In recent surveys conducted at the
2009 Canadian Rheumatology Association Conference and the 2009 Canadian
Digestive Diseases Week, almost half of responding gastroenterologists and
nearly two thirds of responding rheumatologists believe that these chronic
diseases are detrimental to a student's ability to achieve academic success."
    An independent selection committee of leading physicians and patient
representatives from across the country will choose the 2009 UCBeyond
scholarship recipients. Applicants will be evaluated based on a one-page essay
demonstrating how they reach beyond their disease, exhibit perseverance and
empower others, as well as two letters of personal recommendation. The
deadline to apply is June 30, 2009 and the scholarship recipients will be
announced in September 2009.
    "People are constantly surprised to learn that arthritis affects young
children and adolescents," says Steven McNair, President and CEO of The
Arthritis Society, and a volunteer member of the rheumatoid arthritis
scholarship selection committee. "That is why the UCBeyond scholarship program
is so valuable to the arthritis community - it has made a dramatic impact on
the lives of young people by allowing them to pursue their educational goals
and empowering them to overcome challenges the disease imposes on their
    "Students who demonstrated an ability to overcome the effects of their
disease were recognized in 2007 and 2008, and we are delighted that these
scholarships will continue in 2009," says Dr. Kevin Glasgow, CEO of the
Crohn's and Colitis Foundation of Canada - a voluntary, not-for-profit,
medical research foundation dedicated to finding the cure for Inflammatory
Bowel Disease (IBD) and one of the world's leading sources of
non-governmental, funding of IBD research.
    Other supporters of the UCBeyond scholarship program include: Arthritis
Consumer Experts (ACE), the Canadian Rheumatology Association (CRA), the
Canadian Arthritis Patient Alliance (CAPA), the Canadian Association of
Gastroenterology (CAG) and the Canadian Digestive Health Foundation (CDHF).
    Students interested in applying for the 2009 UCBeyond Rheumatoid
Arthritis and Crohn's Disease scholarship program can obtain an application
package from their rheumatologist or gastroenterologist, or visit, or for a downloadable application form.

    About Rheumatoid Arthritis

    RA is a progressive autoimmune disease that causes chronic inflammation
of the joints. It is estimated that five million people suffer from RA
globally with 0.3% to 1% of the population in industrialized countries
suffering from the disease. It is estimated that 320,000 (1 in 100) people
suffer from RA in Canada(3). Women are three times more likely to be affected
than men. Although it can affect people of all ages, the onset of RA usually
occurs between the ages of 35-55.
    Symptoms of RA may include joint stiffness, joint pain, inflammation of
the affected areas and an associated reduction in mobility. These symptoms can
be intermittent and vary in severity from patient to patient. In more severe
cases RA can eventually lead to disability. RA patients are also at a higher
risk of developing other conditions, in particular heart disease, stroke,
infections, lung problems and osteoporosis(4).

    About Crohn's Disease

    Crohn's disease is a chronic, progressive, destructive disorder that
causes inflammation of the gastrointestinal (GI) tract, most commonly at the
end of the small intestine (the ileum) and beginning of the large intestine
(the colon). If not effectively treated, it results in the need for surgery.
Crohn's disease has been estimated to affect as many as 170,000 Canadians.
People with Crohn's can experience an ongoing cycle of flare-up and remission
throughout their lives. Together with ulcerative colitis, Crohn's disease is
an inflammatory bowel disease (IBD).

    About UCB Pharma Canada

    UCB Pharma Canada was officially incorporated in 2006 with the objective
of bringing new-generation therapies to the Canadian market for auto-immune
and central nervous system diseases. UCB Pharma Canada Inc. is dedicated to
bringing new and innovative programs to patients, and to the specialists who
treat them, to help improve the lives of people living with severe diseases.

    About UCB

    UCB, Brussels, Belgium ( is a biopharmaceutical company
dedicated to the research, development and commercialization of innovative
medicines with a focus in the fields of central nervous system and immunology
disorders. Employing approximately 10,000 people in over 40 countries, UCB
generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext
Brussels (symbol: UCB).

    Forward looking statement

    This press release contains forward-looking statements based on current
plans, estimates and beliefs of management. Such statements are subject to
risks and uncertainties that may cause actual results to be materially
different from those that may be implied by such forward-looking statements
contained in this press release. Important factors that could result in such
differences include: changes in general economic, business and competitive
conditions, effects of future judicial decisions, changes in regulation,
exchange rate fluctuations and hiring and retention of its employees.


    (1) Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the
        progression of radiologic changes in rheumatoid arthritis:
        Correlation of radiographic, clinical and laboratory abnormalities.
        Arthritis & Rheumatism , 1971, Vol. 14, No. 6.

    (2) American College of Rheumatology Subcommittee on Rheumatoid Arthritis
        Guidelines. Guidelines for the Management of Rheumatoid Arthritis
        2002 update. Arthritis & Rheumatism, 2002 Vol. 46, No. 2.


    (4) Firestein G, Rheumatoid Arthritis, ACP Medicine WebMD Publishing,
        August 2004

For further information:

For further information: on the UCBeyond Scholarship Program, please
contact: (905) 567-1406 or 1-888-867-1406, Lyndsay Carter, ext. 225 or Amanda
Webster, ext. 222,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890